DELTA 9 CANNABIS INC. , is pleased to announce that on August 30, 2019 it received its renewal license from Health Canada for a term of three years. This license authorizes Delta 9 to cultivate, process and sell cannabis from its Winnipeg production facility. The Company is also pleased to provide investors with an update on cannabis oils sales, cannabis pre-rolls sales, and new product development.
Health Canada License Renewal and Oils Sales Authorization
The Company, through its subsidiary, Delta 9 Bio-Tech Inc., has received its renewed Standard Cultivation and Standard Processing license for cannabis from Health Canada. The Company has fulfilled Health Canada’s rigorous specifications, and successfully passed all inspections.
“Delta 9 employees have worked hard to meet the requirements within Health Canada’s strictly regulated licensing environment. It speaks to the professionalism of our team that it has maintained the high standards of safety, quality and security in accordance with Health Canada’s regulations for licensed producers,” said John Arbuthnot, Chief Executive Officer of Delta 9.
The Company has also received approval from Health Canada for sales of cannabis oil products. The Company has already completed production of several initial batches of its “Odyssey” and “Oasis” lines of ingestible oils and will proceed with sales of these products in the medical and recreational use cannabis markets.
In June this year the Company launched its “Bliss” line of pre-rolled cannabis products, which consist of blended cannabis flower, rolled in a cigarette format, or “joint”, for sale in the medical and recreational use cannabis markets. To date the Company has produced and sold over 75,000 cannabis pre-rolls.
“It is management’s belief that these products will become an increasingly important component of the medical and recreational use cannabis markets in the future,” said John Arbuthnot, Chief Executive Officer of Delta 9. “A continually expanding line of high-quality cannabis products is a major goal for the Company over this year and this is the first of what we hope are several milestones in our progress.”
Products for Future Development
Nanosphere Evolve Products
Delta 9 has acquired an exclusive license in Canada to manufacture and sell products made with the patented technology of Nanosphere Health Sciences Inc. (“NanoSphere”) for the delivery of cannabinoids via nanoparticle technology. The two companies are in the process of developing the first product for Canada; an intraoral cannabis oil containing cannabinoid nanoparticles.
The NanoSphere delivery system for cannabis works by nano-encapsulating active ingredients in phospholipid membranes for transportation through the skin and mucosa into the bloodstream within minutes. Cannabis applications of the technology include transdermal viscous gels, intranasal products and intraoral products, all of which provide rapid results, precise dosages and high bioavailability. The NanoSphere delivery system of cannabis can eliminate the need for inhalation or ingestion of cannabis, offering users a potentially safer and more effective method of consumption.
Dried Sift Cannabis
The Company is currently developing its “Sapphire” line of dried sift cannabis products for the recreational cannabis market which involves sifting the Company’s blended products and refining them, leaving more of the high potency resin glands and less of the low potency plant material. The final product is a yellow/brownish powder and has a potency that is up to triple that of the whole flower dried cannabis materials. The Company plans to release dried sift products in the recreational cannabis market in the third quarter of 2019. Management expects that retail pricing for these products will be up to $30 per gram.
Oils, Extracts, and Derivative Products
The Company continues to develop and expand its in-house oils production capacity and is working with partners regarding its strategy for new cannabis extracts and derivative products once the federal government finalizes its expanded extract regulations, which are expected to become effective in 2019.
About Delta 9 Cannabis Inc.
Delta 9 Cannabis Inc. is a vertically integrated cannabis company focused on bringing the highest quality cannabis products to market. Delta 9’s wholly-owned subsidiary, Delta 9 Bio-Tech Inc., is a licensed producer of medical and recreational cannabis and operates an 80,000 square foot production facility in Winnipeg, Manitoba, Canada. Delta 9 owns and operates a chain of retail stores under the Delta 9 Cannabis Store brand. Delta 9’s shares trade on the Toronto Stock Exchange under the symbol “DN” and on the OTCQX under the symbol VRNDF.
Delta 9大麻公司很高兴地宣布，它于2019年8月30日从加拿大卫生部获得了为期三年的续期许可证。本许可证授权Delta 9从其温尼伯生产设施种植、加工和销售大麻。该公司还很高兴向投资者提供大麻油销售、大麻卷前销售和新产品开发的最新情况。
该公司通过其子公司Delta 9 Bio-Tech Inc.已从加拿大卫生部收到其更新的大麻标准种植和标准加工许可证。公司已达到加拿大卫生部的严格规范，并顺利通过了所有检查。
“Delta 9的员工在加拿大卫生部严格监管的许可环境中努力满足要求。Delta 9的首席执行官John Arbuthnot说：“这充分说明了我们团队的专业精神，我们按照加拿大卫生部对持牌生产商的规定，保持了安全、质量和安保的高标准。”
Delta 9公司首席执行官约翰•阿尔布什诺（John Arbuthnot）表示：“管理层相信，这些产品未来将成为医疗和娱乐用大麻市场日益重要的组成部分。”“不断扩大高品质大麻产品线是公司今年的主要目标，这是我们希望取得进展的几个里程碑中的第一个。”
Delta 9已在加拿大获得独家许可证，可以生产和销售使用NanoSphere Health Sciences Inc.（“NanoSphere”）专利技术生产的产品，通过纳米颗粒技术交付大麻素。这两家公司正在为加拿大开发第一种产品，一种含有大麻素纳米粒的口服大麻油。
Delta 9大麻公司是一家垂直整合的大麻公司，专注于将最高质量的大麻产品推向市场。Delta 9的全资子公司Delta 9 Bio-Tech Inc.是一家获得许可的医疗和娱乐大麻生产商，在加拿大马尼托巴省温尼伯市经营着一个80000平方英尺的生产设施。Delta 9拥有并经营Delta 9大麻商店品牌下的连锁零售店。Delta 9的股票在多伦多证券交易所以“DN”符号进行交易，在OTCQX上以“VRNDF”符号进行交易。